SELLAS Life Sciences Announces Proposed Public Offering
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by SELLAS.
Related news for (SLS)
- Afternoon Watchlist Builds as Busy Biotech, Blockbuster IPs & Big Institutional Bets Power Late-Day Surge
- MoBot’s Stock Market Highlights – 08/13/25 12:00 PM
- Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
- 24/7 Market News Snapshot 13 August, 2025 – ReShape Lifesciences, Inc. Common Stock (NASDAQ:RSLS)
- ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System